XML 29 R20.htm IDEA: XBRL DOCUMENT
v3.25.2

SEGMENT REPORTING | 6 Months Ended
--- | ---
Mar. 31, 2025
SEGMENT REPORTING |
SEGMENT REPORTING | NOTE 13 – SEGMENT REPORTING The Company, its subsidiaries, the VIE and VIE’s subsidiaries mainly manufactures and distributes active pharmaceutical ingredients and TCMD products as well as other by-products in China, AI solutions and insurance business. Currently no revenue is derived from international markets. The following table presents segment information for the six months ended March 31, 2025, 2024 and 2023, respectively: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended March 31, 2025
​ | ​ | Diversified | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Pharmaceutical | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | and Allied | ​ | ​ | ​ | ​ | Insurance | ​ | ​ | ​
​ |  | Products* |  | AI Solutions |  | Business |  | Total
Revenue |  | $ | 9,631,184 |  | $ | 1,104,733 |  | $ | 3,575,497 |  | $ | 14,311,414
Cost of revenue | ​ |  | 8,283,104 | ​ |  | 772,807 | ​ |  | 2,744,070 | ​ |  | 11,799,981
Gross profit | ​ | $ | 1,348,080 | ​ | $ | 331,926 | ​ | $ | 831,427 | ​ | $ | 2,511,433
Depreciation and amortization | ​ | $ | 200,236 | ​ | $ | 146,125 | ​ | $ | 95,729 | ​ | $ | 442,090
Capital expenditures | ​ | $ | 1,035,722 | ​ | $ | 130,835 | ​ | $ | — | ​ | $ | 1,166,557
* | Due to the acquisition of THE Company, the revenue has been reclassified into three categories. Among them, diversified pharmaceutical and allied products includes the former oxytetracycline & licorice products and TCMD, fertilizer, and heparin products and sausage casing.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended March 31, 2024
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ |  | TCMD |  | Fertilizer |  | Sausage casing |  | Total
Revenue |  | $ | 10,755,535 | ​ | $ | 159,199 | ​ | $ | 1,647,865 | ​ | $ | 12,562,599
Cost of revenue | ​ |  | 9,501,675 | ​ | ​ | 104,591 | ​ | ​ | 1,542,311 | ​ | ​ | 11,148,577
Gross profit | ​ | $ | 1,253,860 | ​ | $ | 54,608 | ​ | $ | 105,554 | ​ | $ | 1,414,022
Depreciation and amortization | ​ | $ | 444,832 | ​ | $ | 22,857 | ​ | $ | 87,083 | ​ | $ | 554,772
Capital expenditures | ​ | $ | 685,827 | ​ | $ | 23,771 | ​ | $ | 76,949 | ​ | $ | 786,547
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For six months ended March 31, 2023
​ | ​ | Oxytetracycline | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | & Licorice | ​ | ​ | ​ | ​ | Heparin | ​ | ​ | ​
​ | ​ | products and | ​ | ​ | ​ | ​ | products and | ​ | ​ | ​
​ |  | TCMD |  | Fertilizer |  | Sausage casing |  | Total
Revenue |  | $ | 18,521,112 | ​ | $ | 752,672 | ​ | $ | 9,889,832 | ​ | $ | 29,163,616
Cost of revenue | ​ |  | 16,622,793 | ​ | ​ | 365,813 | ​ | ​ | 9,880,264 | ​ | ​ | 26,868,870
Gross profit | ​ | $ | 1,898,319 | ​ | $ | 386,859 | ​ | $ | 9,568 | ​ | $ | 2,294,746
Depreciation and amortization | ​ | $ | 452,036 | ​ | $ | 22,123 | ​ | $ | 97,282 | ​ | $ | 571,441
Capital expenditures | ​ | $ | 2,570,090 | ​ | $ | 28,098 | ​ | $ | 3,933 | ​ | $ | 2,602,121
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30,
​ | ​ | 2025 | ​ | 2024
Total Assets |  | ​ |  |  | ​ |
Diversified Pharmaceutical and Allied Products | ​ | $ | 154,006,779 | ​ | $ | 53,003,728
AI Solutions | ​ | $ | 22,499,030 | ​ | $ | —
Insurance Business | ​ | $ | 30,887,640 | ​ | $ | —
Total | ​ | $ | 207,393,449 | ​ | $ | 53,003,728
​

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration